Latest news with #MankindPharma
Time of India
13-06-2025
- Health
- Time of India
HealthOK pays tribute to tireless fathers in its Father's Day campaign
Mankind Pharma , India's pharmaceutical company, has launched a new Father's Day campaign for its flagship brand HealthOK pure vegetarian multivitamin tablets. This initiative celebrates fathers across the nation who demonstrate unwavering dedication to their responsibilities without ever getting tired. The campaign positions fathers as " HealthOK Heroes " – real-life superheroes who provide unconditional support to their families especially children while maintaining their energy and enthusiasm for parenthood. Joy Chatterjee, vice president, sales and marketing head, consumer business unit, Mankind Pharma, said, "Our campaign acknowledges that today's fathers seamlessly transition between multiple roles; they are providers who ensure family security, protectors who offer safety, mentors who guide with wisdom, and friends who share in life's joys.' The Father's Day campaign will be backed by a marketing push across digital and traditional platforms. The company stated that HealthOK celebrates the strength of every father and the potential of every child — because when kids are healthier, fathers are happier. Watch the video here:
Time of India
11-06-2025
- Entertainment
- Time of India
This Father's Day, Prega News honours the 'invisible journey' of fathers
HighlightsPrega News, a pregnancy detection kit brand from Mankind Pharma, launched a Father's Day campaign that emphasizes the often-overlooked contributions of expectant fathers during the pregnancy journey. The campaign features stand-up comedian Aashish Solanki portraying an expectant father who humorously attempts to experience the physical challenges of pregnancy, while also highlighting the emotional and practical support that fathers provide. Recent research shows that 95 percent of Indian fathers believe parenting is a shared responsibility, with 94 percent actively participating in household chores and childcare, reflecting a significant shift in traditional gender roles. Prega News , India's pregnancy detection kit brand from Mankind Pharma , has launched a new Father's Day campaign that celebrates the often-overlooked contributions of expectant fathers during the pregnancy journey. The campaign highlights how pregnancy transforms both partners' lives, even when one's journey remains largely invisible to the world. The campaign film features stand-up comedian Aashish Solanki as an expectant father who attempts to experience pregnancy by wearing a belly for a day, undertaking challenges that pregnant women face daily. From picking up objects to sitting comfortably during work calls, the humorous yet enlightening exercise reveals the physical difficulties expectant mothers endure. However, the narrative takes a meaningful turn when his pregnant wife Rashi and her friends arrive, shifting the focus to acknowledge the emotional and practical support that fathers provide throughout the pregnancy journey. "This Father's Day, we wanted to shine a light on the invisible half of pregnancy - the father's journey," said Joy Chatterjee, vice president, sales and marketing head, consumer business unit, Mankind Pharma. 'While the physical changes of pregnancy are visible in mothers, fathers too undergo a significant emotional transformation, taking on the responsibility of ensuring financial security for the growing family, working tirelessly to meet increased household needs, and making countless sacrifices to prepare for parenthood.' The campaign draws inspiration from recent research indicating that 95 per cent of Indian fathers believe that parenting is a shared responsibility, reflecting the evolving dynamics of modern Indian families . This progressive outlook marks a significant departure from traditional gender roles, with 94 per cent of fathers actively participating in household chores and childcare. "Through this campaign, we want to honour the countless ways fathers contribute to the pregnancy journey; from making late-night food runs, planning budgets and providing emotional stability to making major life adjustments and long-term planning for their child's education and healthcare,"Chatterjee added. The film concludes with the powerful message: "Prega News wishes a Happy Father's Day to all the amazing dads whose invisible journey may not be visible, but who stand by their partners through every joy and challenge of parenthood that begins with good news." Watch the video here:
Business Standard
10-06-2025
- Business
- Business Standard
Mankind Pharma allots 57,709 equity shares under ESOP
Mankind Pharma has allotted 57,709 equity shares of face value of Re. 1/- each of the Company to the eligible employees who have exercised their options pursuant to the ESOP Plan. Consequent to the aforesaid allotment, the paid-up share capital of the Company has increased from 41,26,71,039 equity shares to 41,27,28,748 equity shares having face value of Re. 1/- each. Powered by Capital Market - Live News
Mint
30-05-2025
- Health
- Mint
India to introduce more advanced testing for imported blood products to reduce infection risk
New Delhi: The health ministry plans to mandate the use of a faster and more accurate method to test all imported blood products to maintain the highest safety standards and reduce the risk of infection from transfusions. The ministry intends to introduce nucleic acid testing (NAT) to improve the screening of imported blood products for antibodies of the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus and other impurities, an official aware of the matter said. The decision to shift to NAT has already been taken by the regulator, the Drug Controller General of India (DCGI), and the matter was discussed at the Drugs Technical Advisory Board meeting in April. The board is the highest statutory body responsible for advising the Central and state governments on technical matters related to the administration of the Drugs and Cosmetics Act, 1940. Also Read | Banking on blood: Health ministry frames guidelines to curb paid donations, improve efficacy of transfusions With the introduction of NAT, the conventional testing method known as ELISA, or enzyme-linked immunosorbent assay, will be done away with. ELISA, while a powerful tool, has several drawbacks, including the potential for false positive and negative results, apart from being time-consuming. The Department of Pharmaceuticals and the National Institute of Biologicals (NIB) in Noida had issued an alert in October after the NIB found three imported blood products—Berirab-P (used in rabies injections), Hepabig (to prevent hepatitis B virus infection) and Tetglob (used for tetanus treatment)—to be of sub-standard quality. When the Berirab-P and Hepabig samples were tested again at the National Institute of Virology in Pune using an advanced version of polymerase chain reaction, which is more sensitive than ELISA, they passed the test metrics. The set of Tetglob samples sent to a private laboratory that used ELISA were non-reactive. Safety standards Bharat Serums and Vaccines Ltd, now owned by Mankind Pharma, is the only company in the country that imports these lifesaving blood products. Imported blood products are used for the treatment of critically ill patients or those who are suffering thalassemia and other blood-related disorders. These products are tested at government laboratories to ensure they meet safety and quality standards. Also Read | India plans standard evaluation and quality protocols for HMPV' testing kits 'These are tested using conventional methods, but now the plan is to amend the rules to allow an advanced version of testing in line with international practices," the official said. 'NIB also proposed that an amendment may be considered to test blood products by NAT." Queries sent to the health ministry, the Department of Pharmaceuticals and the Mankind Pharma spokesperson remained unanswered till press time. 'NAT testing gives accurate and quick results and nowadays it is highly used. NAT testing is used for tuberculosis and NAT testing was modified during the covid-19 pandemic to detect the coronavirus," a scientist from the Indian Council of Medical Research said, requesting anonymity. 'The ELISA test may sometimes give false results if the viral load in the sample is low. However, PCR and NAT give accurate results even if the viral load is low." Also Read | ICMR and CDSCO develop framework for validation of pathogen identification and antimicrobial susceptibility testing According to an assessment by the National Blood Transfusion Council, the apex policymaking body for issues pertaining to blood and plasma, the clinical requirement of blood in the country is about 14.5 million units per year. The volume of each unit of blood is about 450 ml. In India, the import, manufacture, distribution and sale of drugs, cosmetics and notified medical devices are regulated by the Drugs and Cosmetics Act and the Drugs and Cosmetics Rules, 1945.
Mint
27-05-2025
- Business
- Mint
Mankind to expand gastro, derma presence, says MD Rajeev Juneja
Mankind Pharma is focused on expanding its presence in the gastrointestinal and dermatology segments this year, as it looks at expanding its presence in the chronic segments, managing director Rajeev Juneja toldMintin an interview. 'We are not great in the gastro [segment]...we have decided that we are supposed to work a lot in gastro because it has become semi-chronic, and our inclination is towards the chronic side," Juneja said, adding thatgastro in India is one of the fastest-growing segments. 'Along with this, we are working on derma as well," he said. The gastro segment grew 7.3% year on year in April, according to pharma intelligence platform Pharmarack. Further, Mankind is developing a novel anti-obesity and diabetes drug in-house. The drug candidate, GRP119, is currently in phase 2 trials in Australia, and Juneja said that results are expected in the next six to nine months. In FY25, Mankind signed a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise its novel drug Vonoprazan, to treat Gastroesophageal Reflux Disease (GERD). Also Read: Sun Pharma to ramp up growth-boosting specialty portfolio in FY26 Juneja said that the company is evaluating all options to increase its presence in these therapy areas, including in-licensing products from innovators or small acquisitions. 'No past strategy can be guaranteed for future success. So we need to apply our mind and try to bring some kind of differentiation in whatever we do," said Juneja. 'The point is that once we decide that our intention is that we are supposed to be good on the gastro side, we start searching for avenues, we start searching for people, we start searching for products," he said. The company will also continue to strengthen its leadership in the women's health segment, which received a boost last year through its acquisition of Bharat Serum and Vaccines (BSV). With its foundation strengthened in FY25, Mankind aims to grow 1.2 to 1.3 times the Indian pharmaceutical market. Juneja said this will be driven by its focus on its chronic domestic formulations portfolio. Juneja said the focus is also on growing larger brands, from the current ₹50 crore to ₹100 crore brands for products to ₹500 crore brands. 'This is the strategy we basically want to pursue in future, because we have seen that once you create that kind of a brand, that's a very big entry barrier," he added. BSV acquisition Mankind is on track with the integration of BSV, which it acquired for ₹13,768 crore in October 2024. The integration will be funded through a mix of internal accruals and external debt. Juneja said the company focused on removing the 'extra flab" and bringing in the right talent for the acquired entity in FY25. This year, he expects 18-20% growth from the BSV portfolio. The goal is to increase the reach and awareness of BSV's niche super-speciality products. BSV is working on two biosimilars, the company's investor presentation highlighted, although Juneja declined to share more details on the BSV pipeline. Also Read: Emcure Pharmaceuticals to expand gynaecology, derma portfolio for India market in FY26 Vishal Manchanda, senior vice president of Institutional Equities at Systematix Group, toldMintthat BSV's platform and skillset for making recombinant drugs (created by inserting genes from one species into a host species) can be leveraged to make biosimilars. Select companies in India, including Biocon, are skilled at the recombinant process. However, Manchanda pointed out that Mankind has the potential to scale this up meaningfully. Innovation push 'If you're a pharma company, naturally, you gain respect once you have great R&D," Juneja said. 'We started our own R&D in Mankind 13-14 years back…going forward, we'll be putting a bit more money in the R&D side…our R&D expenses will increase because that would be the future need as well." 'We wish to become a bigger company…our dream is to become India's number one company on the domestic side," Juneja said, adding that 'we need to have certain innovative products, and we are working for that". Mankind's focus on innovation and speciality segments comes as the Indian pharmaceutical market has become more crowded. Most segments already have established market leaders. '…the promoters are realising that there is a challenge to growth. And they know the space they have been playing in is now kind of difficult to expand from where they are, meaningfully expand from where they are. So I think Mankind promoters being extremely committed to India business, they are also kind of prepared on how to take this forward," Manchanda said. 'What they are actually looking for is a bigger avenue to build growth on," he added, referring to Mankind's BSV acquisition. Internal corrections Mankind undertook several internal correction initiatives in the last year, including leadership changes and improving synergies between its divisions, Juneja said. Also Read: Zydus bets big on vaccines and medtech 'If you look at the history of Mankind, in 30 years, we have become the fourth largest company," Juneja said, adding that for any company growing very fast, there comes a time when growth plateaus. 'But once you bring commercial excellence, you bring people from outside…a number of flaws can come in front of you, and you have two choices: Either to remove those flaws gradually without affecting your sales and profit and growth, or second, do it immediately," Juneja said. 'We belong to the second category, and we decided that by March 2025, we'll clean up Mankind from every side," he added.
